Ads
related to: imfinzi immunotherapy for lung cancer- aNSCLC Patient Support
Find Helpful Resources & Get
Answers About A Treatment Option.
- aNSCLC Treatment Option
Visit The Patient Website Today To
Learn About This Treatment Option.
- Patient Support Program
Sign Up For A Patient Support
Program For This aNSCLC Treatment.
- How This Treatment Works
Explore Important Treatment Info
On The Official Patient Website.
- aNSCLC Patient Support
Search results
Results from the WOW.Com Content Network
Imfinzi won approval for use in mid-stage non-small cell lung cancer a year later. In March 2020, the FDA approved Imfinzi to target extensive-stage small-cell lung cancer.
Durvalumab, [8] sold under the brand name Imfinzi, is an FDA-approved immunotherapy for cancer, developed by Medimmune/AstraZeneca. [9] It is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody that blocks the interaction of programmed cell death ligand 1 ( PD-L1 ) with the PD-1 (CD279).
Small cell lung cancer is a highly aggressive form of lung cancer. Imfinzi is a human monoclonal antibody, which works by blocking a tumour's ability to evade and dampen the immune system, while ...
AstraZeneca (AZN) presents follow-up data on Imfinzi from late-stage PACIFIC study evaluating it in lung cancer patients. AstraZeneca's Imfinzi Shows Long-Term Benefits in Lung Cancer Skip to main ...
Cancer immunotherapy ... non-small cell lung cancer, small cell lung cancer, hepatocellular carcinoma, ... Durvalumab (Imfinzi) is a human immunoglobulin G1 kappa ...
It failed phase III clinical trials for gastric cancer. [33] Durvalumab (Imfinzi) is a fully human IgG1 antibody developed by AstraZeneca. Durvalumab is FDA approved for the treatment of urothelial carcinoma and unresectable non-small cell lung cancer after chemoradiation. [34]
Ads
related to: imfinzi immunotherapy for lung cancer